INDIANAPOLIS--Eli Lilly and Company's Gemzar (gemcitabine) is now available for use in the treatment of advanced pancreatic cancer.
"As the first new treatment for pancreatic cancer in several decades, Gemzar represents hope for patients and a breakthrough for Lilly scientists," said August M. Watanabe, MD, executive vice president of the company.
Gemzar, a nucleoside analog, is the first chemotherapy agent to receive FDA clearance based on a unique clinical endpoint--clinical benefit response--designed to objectively assess the effect of the drug on measured disease-related symptoms. In two clinical trials, about one quarter of patients treated with Gemzar demonstrated improvement in symptoms.
Gemzar is indicated as first-line treatment for patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas, and is also indicated for patients previously treated with fluorouracil(Drug information on fluorouracil).